Genprex

Fu Chen, Ph.D.

Director of Formulation Development

Dr. Fu Chen joined Genprex as Director of Formulation Development in August 2021. He is responsible for the development of LNP-gene formulation and delivery platform, as well as analytical method development, qualification, and validation. Dr. Chen has more than 15 years of experience across formulation, analytical method development and organic synthesis in cancer, antiviral and diabetes drug discovery and development.

Prior to joining Genprex, he worked more than four years as the scientific director at Drug Delivery Experts in San Diego to lead a cross-functional team to develop LNP and its agglomerated vesicles delivery system of a peptide drug for diabetes treatment; as well as worked on analytical methods development and qualification. Before that, he spent more than six years in the Bio-Medical Division of Nitto Denko Technology (now changed to Nitto BioPharma Inc.) with increasing responsibilities to develop the LNP-nucleic acid drug for liver fibrosis treatment, polymer-drug conjugates for cancer treatment. He led an analytical team to develop and qualify analytical methods for characterization. He has held other research roles at Biota Inc for antiviral drug discovery, and at Chemical Diversity for CRO services. He has extensive experience in organic synthesis, project management, team and lab operation and management.

Dr. Chen holds a BS and a MS in chemistry from Zhongshan University, China, and a Ph.D. in Materials Engineering from McGill University, Canada.